SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : AutoImmune-AIMM
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Zeev Hed who wrote (282)3/1/1999 8:54:00 PM
From: nanocap  Read Replies (1) of 298
 
Thanks, you may want to note that the company completed enrollment in its Phase III Colloral trial for rheumatoid arthritis in early February. Results of the trial should be available around mid-September.

Secondly, the company just announced an exclusive agreement with Teva Pharmaceuticals for two applications of its technology for oral modulation relative to Teva's COPAXONE multiple sclerosis drug.

There's also been some interesting accumulation of the stock (see SEC filings) over the past six months. For what it's worth.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News